COVID-19 Vaccination in Patients With Cancer and Recipients of Cellular Therapy
Fareed Khawaja, MBBS, and colleagues provide a comprehensive overview of COVID-19 vaccine efficacy and safety among patients with cancer in the United States.
Related Articles
Survival Outcomes Improve With TIL Presence in TNBC
An increased TIL count in the breast tissue was associated with improved distant recurrence-free survival in patients with triple-negative breast cancer.
Durvalumab Combo Yields OS Benefit in Advanced Biliary Tract Cancer
The phase 3 TOPAZ-1 trial of durvalumab plus chemotherapy showed a significant benefit vs chemotherapy alone for patients with advanced biliary tract cancer.
Response Observed With Savolitinib Combo in EGFR, MET, Osimertinib-Resistant NSCLC
A proteogenomic analysis found savolitinib plus osimertinib elicited a response in patients with EGFR-mutated, MET-amplified advanced NSCLC.
COVID-19 and Chemotherapy Association Holds in Pediatric Leukemia/Lymphoma
Pediatric patients with acute lymphoblastic leukemia/lymphoma were less likely to have severe COVID-19 infection.
Olutasidenib Yields Enduring Remissions in Previously Treated IDH1+ AML
Phase 2 findings support olutasidenib as a potentially “valuable” treatment option in IDH1-mutated acute myeloid leukemia.
The Role of a GPRC5D-Targeting Bispecific in Relapsed/Refractory MM
Beth Faiman, PhD, MSN, describes the role of a GRPC5D-targeting bispecific antibody, talquetamab, in the treatment of patients with relapsed/refractory multiple myeloma.
FDA Grants Accelerated Approval to T-DXd in Advanced HER2+ Solid Tumors
Results from 3 DESTINY trials led to the accelerated approval of fam-trastuzumab deruxtecan-nxki for patients with unresectable or metastatic HER2-positive solid tumors.
Post-Surgery Treatment of Localized Kidney Cancer
Sumanta Kumar Pal, MD, FASCO, joins Rohit Gosain, MD, and Rahul Gosain, MD, to discuss risk stratification and treatment practices for patients with localized kidney…
Diagnosing and Treating Blastic Plasmacytoid Dendritic Cell Neoplasm in a Resource-Limited Setting
A recent clinical quandary focused on the diagnosis and treatment of blastic plasmacytoid dendritic cell neoplasm in a resource-limited setting.
FDA Grants Accelerated Approval to T-DXd in Advanced HER2+ Solid Tumors
Results from 3 DESTINY trials led to the accelerated approval of fam-trastuzumab deruxtecan-nxki for patients with unresectable or metastatic HER2-positive solid tumors.